Hsbc Holdings PLC Incyte Corp Put Options Transaction History

Hsbc Holdings PLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	BUY	$56.55 - $66.59 $316,680 - $372,904	5,600 New	5,600 $319,000
Q4 2021 Feb 11, 2022	BUY	$63.34 - $74.11 $943,766 - $1.1 Million	14,900 Added 69.63%	36,300 $0
Q3 2021 Nov 12, 2021	BUY	$68.67 - $84.02 $803,439 - $983,034	11,700 Added 120.62%	21,400 $1.48 Million
Q2 2021 Aug 13, 2021	SELL	$79.87 - $87.53 $1.49 Million - $1.63 Million	-18,600 Reduced 65.72%	9,700 $0
Q1 2021 May 14, 2021	SELL	$76.02 - $100.5 $1.22 Million - $1.62 Million	-16,100 Reduced 36.26%	28,300 $0
Q4 2020 Feb 25, 2021	BUY	$80.74 - $97.7 $1.5 Million - $1.82 Million	18,600 Added 72.09%	44,400 $0
Q3 2020 Nov 12, 2020	SELL	$85.07 - $109.69 $1.49 Million - $1.92 Million	-17,500 Reduced 40.42%	25,800 $2.32 Million
Q2 2020 Aug 14, 2020	SELL	$74.18 - $108.93 $59,344 - $87,144	-800 Reduced 1.81%	43,300 $4.5 Million
Q1 2020 May 15, 2020	BUY	$63.18 - $85.97 $2.21 Million - $3.01 Million	35,000 Added 384.62%	44,100 $3.21 Million
Q4 2018 Feb 13, 2019	BUY	$58.5 - $69.94 $473,850 - $566,514	8,100 Added 810.0%	9,100 $579,000
Q1 2018 May 11, 2018	BUY	$83.06 - $100.98 $83,060 - $100,980	1,000 New	1,000 $85,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.